FDA Issues Warning Letters to Five Online Peptide Sellers, Including Peptide Partners and Peak Performance Peptides

On August 24, 2026, the FDA issued warning letters to at least five online peptide sellers: Peptide Partners LLC, Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, and TXP Innovations LLC, doing business as Tex Peptides. The letters followed FDA reviews of the firms' websites in July 2026 and were posted on the FDA database on September 1, 2026.

The batch is grouped as one event because the letters share one letter date, one issuing office, and one legal theory. That matches how the FDA March 31, 2026 seller letters were treated in this backfill.

The FDA stated that products sold by these firms, including semaglutide, tirzepatide, retatrutide, SS-31 (elamipretide), tesamorelin, and PT-141 (bremelanotide), are unapproved new drugs under the Federal Food, Drug, and Cosmetic Act.

Only firms confirmed in FDA letters are named in this post. The warning letters database is the source for the batch, and three of the individual letters, for Peptide Partners, Peak Performance Peptides, and Royal Peptides, are cited directly below.

A warning letter is an FDA allegation and enforcement step, not a court judgment. For readers, the consistent regulatory point is that selling a molecule that also appears in an approved drug does not transfer that approval. Approval belongs to a specific approved product and its labeled indication only.